<DOC>
	<DOCNO>NCT02555696</DOCNO>
	<brief_summary>This observational project collect tolerability , safety efficacy data routine use Abraxane treatment metastatic breast cancer . Additionally data dosage Abraxane general data disease health status patient collect .</brief_summary>
	<brief_title>Abraxane Treatment Metastatic Breast Cancer</brief_title>
	<detailed_description>This observational program aim gain tolerability , safety efficacy data routine use Abraxane label indication metastatic breast cancer . Additionally data real life dose daily clinical routine analyze . A detailed record medical history include co-morbidities pre-treatment regimen allow analysis impact thereof tolerability , dosage efficacy . This data might also supportive treatment optimization Abraxane Metastatic Breast Cancer ( MBC ) .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>1 . Patients metastatic breast cancer ( accord European Summary Product characteristic ( SmPC ) 2 . Signed Informed Consent 3 . Participants &gt; 18 Years Age 1 . Pregnant lactating female 2 . Neutrophils &lt; 1.5 X 10^9/L 3 . Hypersensivity nabpaclitaxel</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Metastatic Breast Cancer</keyword>
	<keyword>nab-paclitaxel</keyword>
	<keyword>Abraxane</keyword>
</DOC>